H Tanaka1, N Miyazaki, K Oashi, S Tanaka, M Ohmichi, S Abe. 1. Third Department of Internal Medicine, Sapporo Medical University School of Medicine, and the Sapporo Hospital of Hokkaido Railway Company, Sapporo, Japan.
Abstract
BACKGROUND: The ratio of matrix metalloproteinase-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) may be a marker of the balance between airway tissue destruction and repair. TIMP-1 may potentially contribute to the pathogenesis of increased submucosal extracellular matrix deposition in asthma. OBJECTIVE: Our purpose was to assess the variation in sputum MMP-9 and TIMP-1 during acute asthma. METHODS: We evaluated the MMP-9 and TIMP-1 balance in sputa of 16 asthmatic patients admitted with spontaneous exacerbation, conducting measurement before (day 1) and after methylprednisolone infusion therapy (days 2, 3, 5, and 7), and on remission days. RESULTS: Peak expiratory flow and eosinophilic cationic protein levels were significantly (P <.05) improved within 7 days in all patients. Sputum MMP-9 levels on day 2 tended to be lower than on day 1, but not significantly. Zymography revealed that the main enzyme was identified immunologically as MMP-9, and gelatinase activity on day 1 had a tendency to decrease for the following 7 days. The TIMP-1 levels gradually increased until day 5, were significantly (P <.05) high on day 5, and decreased on day 7. The MMP-9/TIMP-1 molar ratios were significantly (P <.05) decreased on days 2, 3, 5, and 7 compared with day 1. Sputum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 molar ratios on day 1 were significantly higher (P <.02) than those on remission days. CONCLUSIONS: An imbalance between MMP-9 and TIMP-1 was present in acute asthma, with an excess of MMP-9 resulting in a high ratio of MMP-9/TIMP-1 before treatment, and over time with glucocorticosteroid the TIMP-1 levels rose, dropping the ratio of MMP-9/TIMP-1. It was suggested that overproduction of MMP-9 and TIMP-1 after asthma exacerbation might contribute significantly to airway tissue remodeling and that TIMP-1 production in acute asthma might not be suppressed by glucocorticosteroid.
BACKGROUND: The ratio of matrix metalloproteinase-9 (MMP-9) and its inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1) may be a marker of the balance between airway tissue destruction and repair. TIMP-1 may potentially contribute to the pathogenesis of increased submucosal extracellular matrix deposition in asthma. OBJECTIVE: Our purpose was to assess the variation in sputum MMP-9 and TIMP-1 during acute asthma. METHODS: We evaluated the MMP-9 and TIMP-1 balance in sputa of 16 asthmatic patients admitted with spontaneous exacerbation, conducting measurement before (day 1) and after methylprednisolone infusion therapy (days 2, 3, 5, and 7), and on remission days. RESULTS: Peak expiratory flow and eosinophilic cationic protein levels were significantly (P <.05) improved within 7 days in all patients. Sputum MMP-9 levels on day 2 tended to be lower than on day 1, but not significantly. Zymography revealed that the main enzyme was identified immunologically as MMP-9, and gelatinase activity on day 1 had a tendency to decrease for the following 7 days. The TIMP-1 levels gradually increased until day 5, were significantly (P <.05) high on day 5, and decreased on day 7. The MMP-9/TIMP-1 molar ratios were significantly (P <.05) decreased on days 2, 3, 5, and 7 compared with day 1. Sputum levels of MMP-9 and TIMP-1 and the MMP-9/TIMP-1 molar ratios on day 1 were significantly higher (P <.02) than those on remission days. CONCLUSIONS: An imbalance between MMP-9 and TIMP-1 was present in acute asthma, with an excess of MMP-9 resulting in a high ratio of MMP-9/TIMP-1 before treatment, and over time with glucocorticosteroid the TIMP-1 levels rose, dropping the ratio of MMP-9/TIMP-1. It was suggested that overproduction of MMP-9 and TIMP-1 after asthma exacerbation might contribute significantly to airway tissue remodeling and that TIMP-1 production in acute asthma might not be suppressed by glucocorticosteroid.
Authors: Edgar Olivas-Calderón; Rogelio Recio-Vega; A Jay Gandolfi; R Clark Lantz; Tania González-Cortes; Cesar Gonzalez-De Alba; John R Froines; Jorge A Espinosa-Fematt Journal: Toxicol Appl Pharmacol Date: 2015-06-03 Impact factor: 4.219
Authors: Max Wohlauer; Ernest E Moore; Christopher C Silliman; Miguel Fragoso; Fabia Gamboni; Jeffrey Harr; Frank Accurso; Frank Wright; James Haenel; David Fullerton; Anirban Banerjee Journal: Crit Care Med Date: 2012-09 Impact factor: 7.598
Authors: H Matsumoto; A Niimi; M Takemura; T Ueda; M Minakuchi; R Tabuena; K Chin; T Mio; Y Ito; S Muro; T Hirai; S Morita; S Fukuhara; M Mishima Journal: Thorax Date: 2005-04 Impact factor: 9.139
Authors: Patricia L Jackson; Xin Xu; Landon Wilson; Nathaniel M Weathington; John Paul Clancy; James Edwin Blalock; Amit Gaggar Journal: Mol Med Date: 2010-01-22 Impact factor: 6.354
Authors: Paola D Vermeer; James Denker; Miriam Estin; Thomas O Moninger; Shaf Keshavjee; Philip Karp; Joel N Kline; Joseph Zabner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-03-06 Impact factor: 5.464
Authors: Michele Y F Kong; Amit Gaggar; Yao Li; Margaret Winkler; J Edwin Blalock; J P Clancy Journal: Int J Med Sci Date: 2008-12-16 Impact factor: 3.738